This inventor holds 4 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignees: Ajou University Industry-Academic Cooperation Foundation, Genesen Co., Ltd., S&k Therapeutics. Active years: 2019-2026.
Company Filing History:
2 out of 382 
1 out of 3 
1 out of 1 Years Active: 2019-2026
Title: Sangdun Choi: Innovator in Immunology
Introduction
Sangdun Choi is a prominent inventor based in Suwon-si, South Korea. He has made significant contributions to the field of immunology, particularly through his innovative research and development of therapeutic agents.
Latest Patents
Sangdun Choi holds a patent for a Toll-like receptor 4 (TLR4) antagonist. This invention provides a peptide that binds to a TLR4/myeloid differentiation factor 2 (MD2) composite. It inhibits the secretion of interleukin-6 (IL-6), nitrogen monoxide (NO), and reactive oxygen species (ROS). Additionally, it prevents the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) and mitogen-activated protein kinases (MAPKs). This is achieved by inhibiting the TLR4 signaling pathway induced by lipopolysaccharide (LPS). The TLR4 antagonist, including the peptide, is designed for preventing or treating autoimmune diseases and inflammatory diseases.
Career Highlights
Sangdun Choi is associated with Genesen Co., Ltd., where he continues to advance his research in immunology. His work has garnered attention for its potential applications in treating various inflammatory conditions.
Collaborations
He collaborates with notable colleagues, including Tae Hyeon Yoo and Seol Hee Park, who contribute to his research endeavors.
Conclusion
Sangdun Choi's innovative work in developing TLR4 antagonists showcases his commitment to advancing medical science. His contributions have the potential to significantly impact the treatment of autoimmune and inflammatory diseases.